Pu'ang Medical Grabs Time Rollover Broker Statistics

PortfolioAlert · 2026-03-22T14:44:22+00:00

Puang Medical's top-tier subscription rush experienced a severe test, with nearly all major brokerages crashing, and many users encountering failed subscription attempts across different time periods. Intermediaries have also begun adjusting their strategies, recommending that users avoid underperforming brokerages.

PortfolioAlert

2026-03-22 14:44:22

Abstract generation in progress

Due to lessons learned from several failed attempts to抢时间. Pu’ang Medical everyone is eager and fully committed. So, this time is a major test for the brokerage channels.

The final result was quite brutal.

Only with good luck could someone抢时间 get 200 shares.

Some brokerages experienced widespread failures.

Bank of China Securities almost everyone failed.

Huabao Securities placed orders at 8:44 and nearly everyone failed.

CITIC Construction Investment failed at 8:34.

Everbright Securities applied at 8:30 and failed.

Ping An Securities failed at 8:45:32.

Guojin Securities placed orders at 8:35 and almost everyone failed.

Guotai Haitong experienced large-scale failures, with some placing orders at exactly 9:15:00 and failing.

Eastmoney placed orders at 6:13 and failed; only by submitting overnight orders in advance could they secure a stable position. Someone failed with 4 accounts at 8:46, losing 1 account.

Galaxy Securities ZGC branch placed an order at 8:32 and failed.

Galaxy Securities Shanghai branch at 8:32:57 also failed.

Some intermediaries explicitly instructed brokerages not to buy new stocks during抢时间.

“Donghai, Guolian Minsheng, Huafu, Shanghai Securities, Dongwu, Bank of China, Huabao, Zhejiang Securities, Galaxy, Guotou, Zhongtai, Shenwan, Ping An, Guotai Haitong”

Of course, smarter intermediaries buy at the post-failure prices.

Everyone can refer to this.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.